Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC.
Author
Olsen, Elise AWhittaker, Sean
Willemze, Rein
Pinter-Brown, Lauren
Foss, Francine
Geskin, Larisa
Schwartz, Lawrence
Horwitz, Steven
Guitart, Joan
Zic, John
Kim, Youn H
Wood, Gary S
Duvic, Madeleine
Ai, Wei
Girardi, Michael
Gru, Alejandro
Guenova, Emmanuella
Hodak, Emmilia
Hoppe, Richard
Kempf, Werner
Kim, Ellen
Lechowicz, Mary Jo
Ortiz-Romero, Pablo
Papadavid, Evangelia
Quaglino, Pietro
Pittelkow, Mark
Prince, H Miles
Sanches, Jose Antonio
Sugaya, Makoto
Vermeer, Maarten
Zain, Jasmine
Knobler, Robert
Stadler, Rudolf
Bagot, Martine
Scarisbrick, Julia
Publication date
2022-08-04
Metadata
Show full item recordAbstract
The number of patients with primary cutaneous lymphoma (PCL) relative to other non-Hodgkin lymphomas (NHLs) is small and the number of subtypes large. Although clinical trial guidelines have been published for mycosis fungoides/Sézary syndrome, the most common type of PCL, none exist for the other PCLs. In addition, staging of the PCLs has been evolving based on new data on potential prognostic factors, diagnosis, and assessment methods of both skin and extracutaneous disease and a desire to align the latter with the Lugano guidelines for all NHLs. The International Society for Cutaneous Lymphomas (ISCL), the United States Cutaneous LymphomaConsortium (USCLC), and the Cutaneous Lymphoma Task Force of the European Organization for the Research and Treatment of Cancer (EORTC) now propose updated staging and guidelines for the study design, assessment, endpoints, and response criteria in clinical trials for all the PCLs in alignment with that of the Lugano guidelines. These recommendations provide standardized methodology that should facilitate planning and regulatory approval of new treatments for these lymphomas worldwide, encourage cooperative investigator-initiated trials, and help to assess the comparative efficacy of therapeutic agents tested across sites and studies.Citation
Olsen EA, Whittaker S, Willemze R, Pinter-Brown L, Foss F, Geskin L, Schwartz L, Horwitz S, Guitart J, Zic J, Kim YH, Wood GS, Duvic M, Ai W, Girardi M, Gru A, Guenova E, Hodak E, Hoppe R, Kempf W, Kim E, Lechowicz MJ, Ortiz-Romero P, Papadavid E, Quaglino P, Pittelkow M, Prince HM, Sanches JA, Sugaya M, Vermeer M, Zain J, Knobler R, Stadler R, Bagot M, Scarisbrick J. Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC. Blood. 2022 Aug 4;140(5):419-437. doi: 10.1182/blood.2021012057Type
ArticlePMID
34758074Journal
BloodPublisher
Elsevierae974a485f413a2113503eed53cd6c53
10.1182/blood.2021012057